As part of the Strategic Alliance Agreement signed this year between Russia and Venezuela, a first shipment of 200,000 vials of insulin prepared by Russian company Geropharm arrived this week at the warehouses of the Socialist Company for Production of Biological Medicines (Espromed BIO) CA , in order to meet the demand of patients with diabetes mellitus.
The agreement signed in the context of the International Economic Forum in St. Petersburg will allow the delivery of more than 5 million units of insulin to Venezuela between 2019 and 2020, which implies a beneficiary population of over 400,000 patients in the National Public Health System (SPNS).
the shipment arrived in the country complying with strict sanitary controls and under safety measures consists of Rinsulin P and Rinsulin NPH, genetically designed human insulins of short and intermediate action. It`s noteworthy in addition to quality, safety and efficacy, such treatment is low cost, which represents a significant saving for Venezuelan State in times of economic war.
In addition to drug supply, the strategic alliance stipulates training of highly qualified Espromed BIO personnel as a preliminary step to development national insulin production, in order to lay foundations for local pharmaceutical safety. Additionally, execution of this project`s emerging as an important step for development of Russian-Venezuelan cooperation in humanitarian field.
Visit to Espromed BIO
Parallel to insulin arrival , a Russian delegation from Geropharm board visited Espromed BIO Biological Plant, in order to learn about the technological potential, operational capacity and human talent of this company attached to the Ministry of Popular Power for Health in its portfolio of vaccines, monoclonal antibodies, erythropoietins, interferons and other biological preparations.
For its part, Geropharm is the leading Russian biotechnology company in the development and production of insulins, since 2016 occupies the first place in sales of genetically human insulin manufacturers.
GEROPHARM is a national manufacturer of biotechnological products providing for medicinal safety of Russia:
- Development and production of medicinal
products to treat socially important
diseases as a fully integrated site
- Investment into technological development and creation of
modern pharmaceutical infrastructure
- Implementation of the tasks in import substitution within
state federal programs
- Development of production of active
- Leadership in diabetology
GEROPHARM was founded in 2001. Today GEROPHARM is a large and efficient business structure, one of the key players at the Russian pharmaceutical market and an expert of the professional community.